Eli LillyLLY
LLY
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Employees: 47,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
49% more first-time investments, than exits
New positions opened: 244 | Existing positions closed: 164
27% more repeat investments, than reductions
Existing positions increased: 1,757 | Existing positions reduced: 1,388
17% more funds holding in top 10
Funds holding in top 10: 327 [Q4 2024] → 383 (+56) [Q1 2025]
12% more capital invested
Capital invested by funds: $604B [Q4 2024] → $676B (+$71.9B) [Q1 2025]
4.48% more ownership
Funds ownership: 82.1% [Q4 2024] → 86.58% (+4.48%) [Q1 2025]
0% less funds holding
Funds holding: 3,845 [Q4 2024] → 3,835 (-10) [Q1 2025]
7% less call options, than puts
Call options by funds: $9.22B | Put options by funds: $9.88B
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$700
15%
downside
Avg. target
$944
15%
upside
High target
$1,124
37%
upside
6 analyst ratings
5 positive
83%
0 neutral
0%
1 negative
17%
UBS Trung Huynh | 28%upside $1,050 | Buy Maintained | 2 May 2025 |
HSBC Rajesh Kumar | 15%downside $700 | Reduce Downgraded | 28 Apr 2025 |
Cantor Fitzgerald Carter Gould | 19%upside $975 | Overweight Initiated | 22 Apr 2025 |
Guggenheim Seamus Fernandez | 13%upside $928 | Buy Maintained | 14 Apr 2025 |
Morgan Stanley Terence Flynn | 37%upside $1,124 | Overweight Maintained | 9 Apr 2025 |
Financial journalist opinion
Based on 62 articles about LLY published over the past 30 days
Neutral
The Motley Fool
1 day ago
1 Growth Stock Down 9% to Buy Right Now
Not many companies that have been around since the late 1800s can claim that they're growth companies. But Eli Lilly (LLY 0.90%) can.
Positive
Reuters
1 day ago
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial
Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an early-stage study, an investor note by brokerage Cantor Fitzgerald showed on Friday.
Positive
Zacks Investment Research
1 day ago
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
Eli Lilly and Company LLY has reached a significant support level, making it an attractive option for investors from a technical standpoint. Earlier this week, the stock broke through its 50-day simple moving average (SMA), indicating a potential short-term bullish trend.
Positive
Benzinga
1 day ago
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
Eli Lilly & Co. LLY may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down.
Positive
The Motley Fool
2 days ago
Down 12%, Should You Buy the Dip on Eli Lilly?
Eli Lilly (LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits -- and as a result, the stock has taken off, climbing more than 170% in three years.
Positive
24/7 Wall Street
2 days ago
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (June 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Negative
CNBC
3 days ago
Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition
Novo Nordisk's drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC's Disruptor 50 List.
Positive
Zacks Investment Research
3 days ago
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
LLY banks on soaring Mounjaro and Zepbound sales to defend its obesity edge amid intensifying competition.
Neutral
GlobeNewsWire
3 days ago
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health
Research will leverage world's first AI-enabled screening platform for mapping the therapeutic potential of secreted signaling proteins, developed by Juvena Collaboration aims to accelerate the discovery of treatments that help individuals maintain and even improve their muscle mass and function REDWOOD CITY, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, today announced it has entered a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) to discover, develop, and commercialize drug candidates that improve muscle health and body composition.
Neutral
The Motley Fool
4 days ago
Should You Buy Eli Lilly Stock Before June 22?
Eli Lilly (LLY 4.33%) stock hasn't been doing too well this year, but that could change later this month. A couple of key events are on the horizon this month during which the company will release new data from studies relating to multiple GLP-1 drugs.
Charts implemented using Lightweight Charts™